Centocor Inc. has filed a post-trial motion in the patentinfringement suit it recently lost to Xoma Corp., asking thecourt to reverse at least some of the jury's verdict, a Xomaspokeswoman said on Friday.

Centocor spokesman Richard Koenig declined to elaborate, butsaid the company may also ask U.S. District Court Judge RobertH. Schnacke to order a new trial.

On Oct. 28, a San Francisco jury found that Centocor(NASDAQ:CNTO) infringed the patent covering Berkeley, Calif.-based Xoma's E5 antibody to treat gram-negative sepsis.

Koenig said the judge would likely rule on the motions inJanuary. After that, Xoma would ask the court for relief.

Xoma (NASDAQ:XOMA) would not comment on what relief it willseek. Centocor of Malvern, Pa., said it expects Xoma to ask foran injunction against the use of Centoxin in the United Statesor for an order requiring Centocor to pay a royalty on Centoxinsales.

(c) 1997 American Health Consultants. All rights reserved.